ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for ESOPHAGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to wipe out esophageal cancer before surgery
Disease control OngoingThis early-phase trial tests whether giving chemoradiation plus the immunotherapy drug pembrolizumab, followed by pembrolizumab and lenvatinib before surgery, can kill more cancer cells in people with esophageal or gastroesophageal junction cancer that hasn't spread. The study in…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Virus therapy joins Chemo-Radiation in fight against esophageal cancer
Disease control OngoingThis early-phase trial tests whether adding a cancer-killing virus called OBP-301 to standard chemotherapy and radiation is safe for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. The virus is designed to infect and destroy tumor cells. Sixtee…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New Dual-Action antibody takes on Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug may keep esophageal cancer at bay after chemoradiation
Disease control OngoingThis study tests whether a PD-1 inhibitor (INCMGA00012) can help prevent esophageal cancer from returning after standard chemoradiation. About 110 adults with locally advanced esophageal squamous cell carcinoma who completed chemoradiation without progression will be randomly ass…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug aims to shrink GI cancers before surgery
Disease control OngoingThis phase 2 trial tests whether giving the immune checkpoint inhibitor IMC-001 before surgery can shrink tumors in people with resectable gastric, esophageal, or liver cancer. About 48 participants will receive two cycles of the drug, then undergo surgery. The main goal is to se…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo therapy aims to fight tough esophageal cancer
Disease control OngoingThis phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard chemoradiation helps people with advanced esophageal cancer that cannot be removed by surgery. About 640 participants will receive either durvalumab or a placebo alongside their cancer treatment…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Esophageal cancer trial mixes chemo, radiation, and immunotherapy
Disease control OngoingThis phase II trial tests whether adding an immunotherapy drug (sintilimab) and immune-supporting agents to a medium-dose chemo-radiation regimen can improve outcomes for people with advanced esophageal cancer. About 50 participants will receive the combination, along with probio…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug aims to fight esophageal cancer when others fail
Disease control OngoingThis phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced esophageal cancer that has worsened after initial treatment. About 497 participants will receive either the new drug or one of several chemotherapies. The goal is to see if …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New cancer drug ALK-N001 enters early human testing
Disease control TerminatedThis early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug combo shows promise in halting esophageal cancer progression
Disease control OngoingThis study tests whether adding tiragolumab to atezolizumab can help control esophageal cancer that hasn't grown after standard chemoradiotherapy. About 760 adults with inoperable esophageal squamous cell carcinoma will receive either the drug combination, atezolizumab alone, or …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Freezing tumors to boost cancer treatment: early trial underway
Disease control OngoingThis early-phase trial tests a freezing treatment called cryotherapy, given before and during standard chemoradiation, for people with locally advanced esophageal cancer. The main goal is to find the safest number of cryotherapy sessions. Researchers will also check if the freezi…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental drug cocktail aims to shrink esophageal tumors before surgery
Disease control OngoingThis early-phase trial tests whether combining two drugs—camrelizumab (an immunotherapy) and palbociclib (a targeted therapy)—is safe and feasible when given before surgery for esophageal cancer. Six adults with resectable esophageal squamous cell carcinoma will receive the drugs…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New cancer drug YL201 enters human testing for advanced tumors
Disease control OngoingThis study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Esophageal cancer drug combo trial pulled before it began
Disease control TerminatedThis early-stage trial aimed to test a new drug called S095033 combined with the chemotherapy paclitaxel in people with advanced or metastatic esophageal squamous cell carcinoma. The goal was to check safety, tolerability, and signs of tumor shrinkage. However, the study was with…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New dual-action antibody enters early trials for tough-to-treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called MCLA-129, a bispecific antibody that targets two cancer-related proteins (EGFR and c-MET). It is for people with advanced non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or colorectal ca…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New cancer drug ABBV-400 enters early human testing
Disease control OngoingThis early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo therapy shows promise for tough esophageal cancer
Disease control OngoingThis study tests adding two drugs, nivolumab and cetuximab, to standard chemoradiation for people with a type of esophageal cancer that hasn't spread far. The goal is to see if this combination can make tumors disappear before surgery. The study involves 12 adults who haven't had…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Baruch Brenner • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Promising cocktail of drugs aims to wipe out esophageal tumors before surgery
Disease control ENROLLING_BY_INVITATIONThis phase II trial tests whether adding two targeted drugs (nimotuzumab and camrelizumab) to standard chemotherapy before surgery can improve outcomes for people with locally advanced esophageal cancer. About 48 participants will be randomly assigned to receive the combination o…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Immunotherapy before standard treatment may boost survival in esophageal cancer
Disease control OngoingThis phase 3 trial tests whether adding immunotherapy (sintilimab) and chemotherapy before standard chemoradiotherapy helps people with inoperable esophageal cancer live longer and reduces the chance of the cancer coming back. About 242 adults aged 18-75 with stage 2-4 esophageal…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Promising combo aims to shrink esophageal tumors before surgery
Disease control OngoingThis study tests whether adding the drug serplulimab to standard chemotherapy before surgery can help people with a certain type of esophageal cancer. The goal is to shrink tumors more effectively and lower the chance of cancer coming back. About 48 adults with stage II to IVA es…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New combo therapy aims to boost survival in tough esophageal cancer cases
Disease control OngoingThis phase 2 study tests whether adding the immunotherapy drug tislelizumab to chemotherapy after standard chemoradiation can improve outcomes for people with locally advanced esophageal cancer who are at high risk. About 80 participants will receive the combination before surger…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sichuan Cancer Hospital and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New combo therapy shows promise in shrinking esophageal tumors before surgery
Disease control OngoingThis early-phase study tests whether combining the immunotherapy drug camrelizumab with standard radiation before surgery can help shrink tumors in people with esophageal cancer. About 25 patients will receive the combination, then undergo surgery 4-8 weeks later. Researchers wil…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Could a blood vessel blocker boost esophageal cancer treatment?
Disease control OngoingThis phase 2 trial tests whether adding the drug apatinib to standard chemotherapy and radiation helps people with advanced esophageal cancer that cannot be removed by surgery. About 170 participants will receive either the standard treatment or the standard treatment plus apatin…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug shows promise against tough cancers
Disease control OngoingThis study tests a drug called sacituzumab govitecan in 53 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug can shrink tumors. Researchers will also track how long any response lasts and how well the drug contro…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
AI reads scans to spot esophageal cancer and predicts best treatment path
Diagnosis OngoingThis study tests two AI models that analyze endoscopy and CT images to diagnose esophageal cancer and predict how deep the tumor has grown. The goal is to help doctors decide if a patient can be treated with a less invasive endoscopic procedure or needs more aggressive therapy. T…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Sponsor: Shanghai Zhongshan Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
AI reads endoscopy images to spot dangerous esophageal tumors
Diagnosis OngoingThis study looks at whether artificial intelligence can accurately determine the depth of early esophageal cancer from endoscopic images. Researchers will review past records and images from 890 patients who had their tumors removed. The goal is to see if AI can help doctors deci…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Sponsor: Fudan University • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
AI takes on esophageal cancer: could it spot the disease earlier?
Knowledge-focused ENROLLING_BY_INVITATIONThis study is testing whether an artificial intelligence (AI) model can help doctors better detect, diagnose, and treat esophageal cancer. Researchers will feed de-identified data from 12,000 patients receiving routine care into the AI and compare its recommendations to standard …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Sponsor: The First Affiliated Hospital of Henan University of Science and Technology • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Can we predict who will benefit from immunotherapy? new study aims to find out.
Knowledge-focused OngoingThis study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists dig into past cases to find best brain tumor treatments for stomach cancer patients
Knowledge-focused OngoingThis study reviews medical records from 230 adults with stomach or esophagus cancer that spread to the brain. Researchers want to see which local treatments (like surgery or radiation) worked best and how long patients lived. The goal is to gather information to help doctors make…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Sponsor: Blokhin's Russian Cancer Research Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC